New Drug: Cosibelimab for Cutaneous SCC
Study
Open-label multicenter, phase I trial (NCT03212404) |
Metastatic or locally advanced cutaneous SCC |
Cosibelimab 800 mg q2wks (n=78) |
Efficacy
ORR: 47.4% |
mDoR: Not reached |
Safety
Fatigue (26.9%), rash (16.7%), and anemia (15.4%) |
J Immunother Cancer 2023 Oct;11(10):e007637
http://doi.org/10.1136/jitc-2023-007637
Reviewed by Ulas D. Bayraktar, MD on Dec 16, 2024
